Product Program year 2021 Source: CMS Open Payments

Lexiscan

Drug Hospital And Transplant

NDC 0469-6501-89

Open in the dashboard

General payments

$191,735

6,249 payments

Research payments

$205,467

10 payments

Through program year 2021, $191,735 in general payments and $205,467 in research payments were reported against Lexiscan (Hospital And Transplant).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

5 rows
Year Kind Amount Payments
2021 General $104,623 3,633
2021 Research $119,100 5
2020 General $86,525 2,585
2020 Research $86,368 5
2019 General $586 31

Breakdown

Who paid General payments · program years 2019–2021
  1. Astellas Pharma US Inc $191,488 6,245 payments
  2. Astellas Pharma Global Development $247 4 payments
Top recipients General payments · program year 2021
  1. Frederman Concepcion Cardiovascular Disease · Chicago, IL $4,568 4% · 3 payments
  2. Vikram Arora Cardiovascular Disease · Birmingham, AL $4,162 4% · 3 payments
  3. Ochsner Clinic Foundation Teaching hospital · LA $4,000 4% · 2 payments
  4. Elizabeth Cosmai Cardiovascular Disease · Fort Myers, FL $3,741 4% · 6 payments
  5. Ernest Belezzuoli Nuclear Medicine · San Diego, CA $3,640 3% · 5 payments

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2021.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2021
  1. Cardiovascular Disease Internal Medicine $43,615 49% · 942 practitioners
  2. Interventional Cardiology Internal Medicine $10,793 12% · 315 practitioners
  3. Nurse Practitioner, Family Nurse Practitioner $6,348 7% · 215 practitioners
  4. Physician Assistant $4,133 5% · 124 practitioners
  5. Nuclear Medicine $3,947 4% · 8 practitioners

The top 5 of 52 specialties; each share is of general payments naming this product to practitioners with a specialty in 2021. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2021
  1. Florida $21,002 20% · 320 recipients
  2. Texas $13,805 13% · 354 recipients
  3. California $13,184 13% · 205 recipients
  4. Alabama $7,003 7% · 79 recipients
  5. Illinois $6,158 6% · 52 recipients

The top 5 of 44 states; each share is of general payments naming this product in 2021 where a state was reported.

The top 25 states, free in the app

Given in the clinic

Part B · billing code
Medicare Part B billing codes matched to LEXISCAN
Billing code Providers Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 6,356 2,216,463 $11,810,171

Drugs given by a clinician are billed to Medicare Part B, not Part D. The product is tied to a billing code through the NDC on CMS's crosswalk, which was published for a later quarter than the payments, so a code that changed in between can be missed. Providers with fewer than 11 patients for the code are not published. Medicare's payment here is what it paid for the services, to the billing practice.

6,249 general · 10 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2021

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record